SAR.L
Sareum Holdings plc [SAR.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SAR.L Stock Summary
Top 10 Correlated ETFs
SAR.L
Top 10 Correlated Stocks
SAR.L
In the News
SAR.L Financial details
Company Rating
Neutral
Market Cap
12.12M
Income
-7.02M
Revenue
0
Book val./share
0.01
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
20 Mar 2024
P/E
-18.7
Forward P/E
-
PEG
-0.86
P/S
-
P/B
35.22
P/C
2675
P/FCF
-12.9
Quick Ratio
1.15
Current Ratio
2.28
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.1
EPS next Y
-
EPS next Q
-
EPS this Y
46.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
38.91%
-
-
-
-
SMA20
-33.33%
SMA50
-65.22%
SMA100
-74.6%
Inst Own
0%
Inst Trans
0%
ROA
-108%
ROE
-79%
ROC
-2.24%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.0-149.0
52W High
-82.05%
52W Low
+167.5%
RSI
56
Rel Volume
12.33
Avg Volume
664.96K
Volume
8.2M
Perf Week
94.55%
Perf Month
-23.57%
Perf Quarter
-58.85%
Perf Half Y
-65.48%
-
-
-
-
Beta
-0.785
-
-
Volatility
4.75%, 7.76%
Prev Close
30.49%
Price
26.75
Change
58.66%
SAR.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.03 | -0.02 | -0.02 | -0.03 | -0.05 | |
| Operating cash flow per share | -0.02 | -0.01 | -0.02 | -0.03 | -0.05 | |
| Free cash flow per share | -0.02 | -0.01 | -0.02 | -0.03 | -0.05 | |
| Cash per share | 0.02 | 0.03 | 0.04 | 0.06 | 0.01 | |
| Book value per share | 0.02 | 0.03 | 0.04 | 0.06 | 0.02 | |
| Tangible book value per share | 0.02 | 0.03 | 0.04 | 0.06 | 0.02 | |
| Share holders equity per share | 0.02 | 0.03 | 0.04 | 0.06 | 0.02 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 12.3M | 16.17M | 187.83M | 137.05M | 85.09M | |
| Enterprise value | 11.38M | 14.37M | 185.14M | 132.79M | 84.09M | |
| P/E ratio | -8.47 | -16.4 | -125.19 | -63.1 | -26.66 | |
| Price to sales ratio | 0 | 342.56 | 0 | 0 | 0 | |
| POCF ratio | -9.73 | -19.89 | -119.59 | -64.31 | -26.04 | |
| PFCF ratio | -9.73 | -19.81 | -119.59 | -64.22 | -26.04 | |
| P/B Ratio | 11.24 | 8.97 | 67.2 | 31.64 | 73.8 | |
| PTB ratio | 11.24 | 8.97 | 67.2 | 31.64 | 73.8 | |
| EV to sales | 0 | 304.37 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -6.82 | -13.13 | -108.72 | -51.57 | -20.9 | |
| EV to operating cash flow | -9.01 | -17.67 | -117.88 | -62.31 | -25.74 | |
| EV to free cash flow | -9.01 | -17.6 | -117.88 | -62.23 | -25.74 | |
| Earnings yield | -0.12 | -0.06 | -0.01 | -0.02 | -0.04 | |
| Free cash flow yield | -0.1 | -0.05 | -0.01 | -0.02 | -0.04 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.55 | 1.65 | 1.58 | 1.65 | 0.25 | |
| Current ratio | 8.23 | 10.06 | 10.74 | 10.46 | 2.28 | |
| Interest coverage | 0 | 0 | 0 | -2.58K | 0 | |
| Income quality | 0.75 | 0.73 | 0.91 | 0.83 | 0.81 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 24.2 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 11.64 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | -0.07 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -5.14 | 0 | -1.5 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.11 | 0.1 | 0.15 | 0.21 | 0.13 | |
| ROIC | -1.32 | -0.55 | -0.54 | -0.5 | -2.76 | |
| Return on tangible assets | -1.17 | -0.49 | -0.49 | -0.45 | -1.58 | |
| Graham Net | 0.01 | 0.03 | 0.04 | 0.06 | 0.01 | |
| Working capital | 1.06M | 1.8M | 2.77M | 4.31M | 1.11M | |
| Tangible asset value | 1.09M | 1.8M | 2.8M | 4.33M | 1.15M | |
| Net current asset value | 1.06M | 1.8M | 2.77M | 4.31M | 1.11M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 284.57K | 242.71K | 258.2K | 410.7K | 739.5K | |
| Average payables | 165.19K | 172.73K | 149.19K | 243.42K | 540.5K | |
| Average inventory | -284.57K | -242.71K | -258.2K | -410.7K | -250K | |
| Days sales outstanding | 0 | 1.51K | 0 | 0 | 0 | |
| Days payables outstanding | 6.7K | 0 | 33.5K | 70.63K | 253.31K | |
| Days of inventory on hand | -13.25K | 0 | -107.82K | -91.25K | 0 | |
| Receivables turnover | 0 | 0.24 | 0 | 0 | 0 | |
| Payables turnover | 0.05 | 0 | 0.01 | 0.01 | 0 | |
| Inventory turnover | -0.03 | 0 | 0 | 0 | 0 | |
| ROE | -1.33 | -0.55 | -0.54 | -0.5 | -2.77 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
| Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | -0.02 | -0.02 | -0.03 | -0.04 | |
| Operating cash flow per share | -0.01 | -0.02 | -0.02 | -0.03 | -0.04 | |
| Free cash flow per share | -0.01 | -0.02 | -0.02 | -0.03 | -0.04 | |
| Cash per share | 0.08 | 0.06 | 0.04 | 0.01 | 0.01 | |
| Book value per share | 0.08 | 0.06 | 0.04 | 0.02 | 0.01 | |
| Tangible book value per share | 0.08 | 0.06 | 0.04 | 0.02 | 0.02 | |
| Share holders equity per share | 0.08 | 0.06 | 0.04 | 0.02 | 0.01 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0.01 | |
| Market cap | 164.84M | 137.84M | 56.16M | 85.09M | 41.78M | |
| Enterprise value | 159.23M | 133.58M | 53.22M | 84.09M | 41.37M | |
| P/E ratio | -48.09 | -26.21 | -9.71 | -12.18 | -4.16 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -202.76 | -104.66 | -42.54 | -44.64 | -15.66 | |
| PFCF ratio | -202.51 | -104.5 | -42.54 | -44.64 | -15.66 | |
| P/B Ratio | 29.03 | 31.83 | 19.47 | 73.8 | 100.2 | |
| PTB ratio | 29.03 | 31.83 | 19.47 | 73.8 | 100.2 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -156.57 | -85.74 | -30.46 | -36.56 | -16.32 | |
| EV to operating cash flow | -195.85 | -101.43 | -40.32 | -44.12 | -15.51 | |
| EV to free cash flow | -195.61 | -101.27 | -40.32 | -44.12 | -15.51 | |
| Earnings yield | -0.01 | -0.01 | -0.03 | -0.02 | -0.06 | |
| Free cash flow yield | 0 | -0.01 | -0.02 | -0.02 | -0.06 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 5.52 | 2.73 | 1.68 | 0.43 | 0.16 | |
| Current ratio | 29.54 | 10.46 | 7.22 | 2.28 | 3.93 | |
| Interest coverage | 0 | 0 | 0 | 0 | -3.33 | |
| Income quality | 0.95 | 1 | 0.91 | 1.09 | 1.06 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -1 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.16 | 0.17 | 0.14 | 0.1 | 0.07 | |
| ROIC | -0.15 | -0.3 | -0.51 | -1.51 | -4.66 | |
| Return on tangible assets | -0.15 | -0.27 | -0.43 | -0.86 | -1.28 | |
| Graham Net | 0.08 | 0.06 | 0.04 | 0.01 | 0.02 | |
| Working capital | 5.65M | 4.31M | 2.86M | 1.11M | 1.43M | |
| Tangible asset value | 5.68M | 4.33M | 2.89M | 1.15M | 1.48M | |
| Net current asset value | 5.65M | 4.31M | 2.86M | 1.11M | 1.43M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 17.42K | 41.4K | 0 | 0 | |
| Days of inventory on hand | 0 | -22.5K | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.01 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.15 | -0.3 | -0.5 | -1.51 | -6.02 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
SAR.L Frequently Asked Questions
What is Sareum Holdings plc stock symbol ?
Sareum Holdings plc is a GB stock and trading under the symbol SAR.L
What is Sareum Holdings plc stock quote today ?
Sareum Holdings plc stock price is $26.75 today.
Is Sareum Holdings plc stock public?
Yes, Sareum Holdings plc is a publicly traded company.
Company Profile
- Volume Average 664.96K
- Market Capitalization 12.12M
- Employee 5
- CEO Dr. Timothy John Mitchell Ph.D.
- Headquarters Cambridge,GB
- IPO Date 2004-10-11
-
Website
https://www.sareum.com 
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
